scispace - formally typeset
R

Robin M. Murray

Researcher at King's College London

Publications -  1583
Citations -  128883

Robin M. Murray is an academic researcher from King's College London. The author has contributed to research in topics: Psychosis & Schizophrenia. The author has an hindex of 171, co-authored 1539 publications receiving 116362 citations. Previous affiliations of Robin M. Murray include University of Cambridge & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole: a 123I IBZM single photon emission tomography (SPET) study

TL;DR: The preliminary evidence suggests that sertindole’s decreased tendency to induce EPS at clinically therapeutic doses is not due to limited occupancy of striatal D2 receptors in vivo, and as is the case for risperidone, patients are protected from EPS by some other intrinsic effect of the drug.
Journal ArticleDOI

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

TL;DR: These findings provide the first large-scale evidence that FEP patients with a history of daily use of high-potency cannabis present with more positive and less negative symptoms, compared with those who never used cannabis or used low-potencies types.
Journal ArticleDOI

Further evidence for shared genetic effects between psychotic bipolar disorder and P50 suppression: a combined twin and family study.

TL;DR: Bipolar disorder was significantly associated with a diminished P50 suppression ratio and decreased C–T amplitude difference and shared genetic factors were the main source of these associations.
Journal ArticleDOI

A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

TL;DR: In this paper, the authors suggest that when antipsychotics are reduced, it should be done gradually (over months or years) and in a hyperbolic manner (to reduce D2 blockade "evenly"): i.e., reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent approximately to a reduction of 5 (or 10) percentage points of its D2 receptor blockade, sequentially (so that reductions become smaller and smaller in size as total dose decreases), at intervals of 3-6 months, titrated to individual tolerance